Capstan Medical develops technology for the treatment of structural heart disease by combining surgical robotics with catheter-based technology and next generation implants to repair and replace heart valves.

Capstan Medical

At Capstan Medical, we’re driven by an unwavering commitment to transforming the treatment of structural heart disease. By merging surgical robotics with catheter-based technology and next generation implants, we’ve pioneered a patient-optimized approach to repair and replace heart valves.

Heart disease continues to be a leading cause of death in the U.S., claiming the lives of nearly 700,000 Americans each year.

Although many cardiovascular treatments have improved and become less invasive, there are still procedures that need improvements. Innovation in this space continues to unfold, promising even better outcomes, faster recovery, and less invasive procedures.

In this LSI USA ‘24 panel, we heard from innovators who are building in this space, and the strategics and investors who have dedicated decades to advancing this field. Together they share recent advances, emerging trends, and the investment landscape fueling these innovations.

Featured Panelists:
• JD Friedland (Moderator), Managing Director, Ventures, Cleveland Clinic
• Maggie Nixon, CEO, Capstan Medical
• Donald E Bobo Jr, Corporate VP, Edwards Lifesciences
• Jacques Essinger, CEO, Polares Medical
• William Phillips, Founder & Managing Partner, Alruna Advisors

The full panel, “Structural Heart Innovation in Medtech's Era of Change” is available on our website and YouTube channel.

Capstan Medical's Social Summer Fun! One (of MANY) benefits to being located in Santa Cruz is access to the beach! The team has gathered together for BBQ's, intern socials, beach bonfires, and of course tie-dying to equip us for our weekly Tie-Dye Tuesday!

Great recap Chris! Glad you liked hearing what Capstan Medical is up to!

Day One in the books for #SRS2024. 

Outstanding day. 

Steve Bell opened up and shared his thoughts and insights that was based on evidence and trends as to where the surgical robotic market in heading.

Dave Rosa from Intuitive as usual was insightful, candid and transparent. As transparent as a publicly traded company can be. Refreshing, given some of the other circle-talking that occurs from other public companies that are here.

The investor panel is always enlightening. As well as revealing as to what are the investors NOT talking about. 

I was surprised that no time was given to the rapidly changing centers of care and how that will greatly influence the entire market from form factors, pricing, investments, sales forces, etc.

The debate around the details of the path over the period of the next 2-5 years would be fair.

- Do 30%? 50%? 75% of procedures convert to robotics?
- What verticals will emerge and adopt at a greater rate than others?
- What companies will lead in each category?
- Where will the procedures take place?
- What does the pricing model look like?
- Are the systems straight up purchased? Price per Procedure? Surgery as a Service?

Debate away

But stepping out over the next 15-20 years, those debate points become irrelevant and moot.

Surgical robotics will be the rule and not the exception.
The definition of "surgical robotics" will also evolve.

A finer stratification of robots, patient selection, sites of care will create great companies and careers.

Companies that are not even born yet will likely dominate a good number percentage of surgical robotic verticals.

Dragonfly - A TMG Company had our full field studio on site, right in the middle of the mosh pit.

Thanks to 
Maggie Nixon from Capstan Medical
Pedro Costa from Interventional Systems
Scott Huennekens and Ben Lundgren from On Target Laboratories

And to Anne Osdoit and Jeffery Alvarez from Moon Surgical for the reveal of the Maestro on Wheels ribbon cutting.

See you at Day 2.

So exciting to see lots of amazing things happening in robotic surgery at #SRS2024. It was a privilege to have our CEO Maggie Nixon be on a panel with so may impactful up and coming robotically enabled technologies!

On May 8th, Jim Hammerand of Medical Design and Outsourcing interviewed Capstan Medical's CEO Maggie Nixon. Check out the article here: https://lnkd.in/g8tyD_9t

Capstan Medical's CEO Maggie Nixon was honored to participate in LSI's structural heart innovation panel alongside such great leaders in the field: JD Friedland, Donald E Bobo Jr, Jacques Essinger, and William Phillips. Looking forward to continuing the conversation as we all strive to transform the available treatments for structural heart disease!

Capstan Medical is excited to kick off the new year by announcing our newly established Clinical Advisory Board: Dr. Mark Webster at University of Auckland and Auckland City Hospital, Dr. Charanjit (Chet) Rihal at Mayo Clinic and Dr. Gorav Ailawadi, MD, MBA at University of Michigan. Strong collaboration between doctors and engineers is powerful fuel for groundbreaking innovation. These clinicians bring a depth of experience and skill that is unparalleled and we are thrilled to welcome them to the Capstan team!

Capstan Medical just wrapped up their very first Tech Suite at the TCT conference!  It was amazing to share the Capstan Medical vision and technology with clinicians, investors and key suppliers alike. A fantastic week of learning and building partnerships to create a new standard for structural heart intervention.  Onward!

msh id	COM:CAPSTANMEDICAL
symbol	-
name	Capstan Medical
homepage url	https://capstanmedical.com
country	US
sector	Healthcare & Health Services
industry	Medical Devices
market	PRIVATE
employee count	-
crunchbase url	-
linkedin url	https://www.linkedin.com/company/capstanmedical
founders	-

market cap	-
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-
growth cost of revenue	-
growth depreciation and amortization	-
growth ebitda	-
growth ebitda ratio	-
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	-
growth gross profit ratio	-

CAPS

COM:CAPSTANMEDICAL

Capstan Medical

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	-
cost of revenue	-
depreciation and amortization	-
ebitda	-
ebitda ratio	-
eps	-
eps diluted	-
operating expenses	-
operating income	-
operating income ratio	-

accounts receivables	-
capital expenditure	-
cash at beginning of period	-
cash at end of period	-
inventory	-
working capital ttm	-

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-